Literature DB >> 21604987

Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.

Geraldine Blanchard-Rohner1, Andrew J Pollard.   

Abstract

The polysaccharide-encapsulated bacteria, Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae are important causes of invasive bacterial infection in childhood, accounting for most of the cases of bacterial pneumonia and meningitis worldwide. Protein-polysaccharide conjugate vaccines have been developed over the last 20 years and have proven very effective in controlling these infections. Although studies have consistently shown that herd immunity is critical for population protection, long-term individual protection against polysaccharide-encapsulated bacteria appears to depend on persisting antibody and, perhaps to a lesser extent, immunological memory. However, some studies have reported that the concentration of serum antibody and vaccine effectiveness are not sustained after infant immunization, despite persistence of immunological memory. In this article, we detail the mechanisms of protection against invasion by encapsulated bacteria, describe the age-dependent B-cell and antibody responses to protein-polysaccharide conjugate vaccines and propose strategies to guarantee protection during periods of increased disease burden.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21604987     DOI: 10.1586/erv.11.14

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  21 in total

1.  Polysaccharide-specific B cell responses to vaccination in humans.

Authors:  Ruth Mitchell; Dominic F Kelly; Andrew J Pollard; Johannes Trück
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

2.  The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Andrew D Cox; Frank St Michael; Evgeny V Vinogradov; Brad Spellberg; Nicole R Luke-Marshall; Anthony A Campagnari
Journal:  Infect Immun       Date:  2013-01-07       Impact factor: 3.441

3.  Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study.

Authors:  Grant A Mackenzie; Isaac Osei; Rasheed Salaudeen; Ousman Secka; Umberto D'Alessandro; Ed Clarke; Jonas Schmidt-Chanasit; Paul V Licciardi; Cattram Nguyen; Brian Greenwood; Kim Mulholland
Journal:  Trials       Date:  2022-01-15       Impact factor: 2.728

4.  A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial.

Authors:  Grant A Mackenzie; Isaac Osei; Rasheed Salaudeen; Ilias Hossain; Benjamin Young; Ousman Secka; Umberto D'Alessandro; Arto A Palmu; Jukka Jokinen; Jason Hinds; Stefan Flasche; Kim Mulholland; Cattram Nguyen; Brian Greenwood
Journal:  Trials       Date:  2022-01-24       Impact factor: 2.728

Review 5.  Listeria monocytogenes: a promising vehicle for neonatal vaccination.

Authors:  Zach Z Liang; Ashley M Sherrid; Anu Wallecha; Tobias R Kollmann
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

Review 6.  Immune response to vaccine adjuvants during the first year of life.

Authors:  Ofer Levy; Stanislas Goriely; Tobias R Kollmann
Journal:  Vaccine       Date:  2012-10-18       Impact factor: 3.641

Review 7.  The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?

Authors:  Martin C J Maiden
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

8.  Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.

Authors:  Els van Westen; Alienke J Wijmenga-Monsuur; Harry H van Dijken; Jacqueline A M van Gaans-van den Brink; Betsy Kuipers; Mirjam J Knol; Guy A M Berbers; Elisabeth A M Sanders; Nynke Y Rots; Cécile A C M van Els
Journal:  Clin Infect Dis       Date:  2015-04-01       Impact factor: 9.079

9.  A universal polysaccharide conjugated vaccine against O111 E. coli.

Authors:  Gabrielle R Andrade; Roger R C New; Osvaldo A Sant'Anna; Neil A Williams; Rosely C B Alves; Daniel C Pimenta; Hugo Vigerelli; Bruna S Melo; Letícia B Rocha; Roxane M F Piazza; Lucia Mendonça-Previato; Marta O Domingos
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

10.  Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.

Authors:  Alienke J Wijmenga-Monsuur; Els van Westen; Mirjam J Knol; Riet M C Jongerius; Marta Zancolli; David Goldblatt; Pieter G M van Gageldonk; Irina Tcherniaeva; Guy A M Berbers; Nynke Y Rots
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.